Item 8.01 Other Events.
On October 7, 2021, ORIC Pharmaceuticals, Inc. (the "Company") issued a press
release announcing (i) initial clinical data from its ongoing Phase 1b study
evaluating ORIC-101, a glucocorticoid receptor antagonist, in combination with
enzalutamide, in patients with metastatic prostate cancer progressing on
enzalutamide and (ii) preclinical data on ORIC-114, a brain penetrant, orally
bioavailable, irreversible inhibitor designed to selectively target EGFR and
HER2 with high potency against exon 20 insertion mutations. A copy of the press
release is attached hereto as Exhibit 99.1, which is incorporated herein by
reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press Release dated October 7, 2021.
104 Cover Page Interactive Data File (formatted as Inline XBRL).
-2-
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses